A multicenter controlled, randomized, open trial of interferon α2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C

Blood

Volumn 89, Issue 10, 1997, Pages 3529-3533

  Rumi, Maria Grazia ^b   Santagostino, Elena ^b   Morfini, M ^b   Gringeri, A ^b   Tagariello, G ^b   Chistolini, A ^b   Pontisso, Patrizia ^b   Tagger, A ^b   Colombo, M ^a   Mannucci, P M ^b  

^a Institute of Internal Medicine   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DNA DETERMINATION; DRUG EFFICACY; FATIGUE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEMOPHILIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; VIREMIA;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOLOGICAL RESPONSE MODIFIERS; FLAVIVIRIDAE; FOLLOW-UP STUDIES; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS C; HEPATITIS, VIRAL, HUMAN; HIV SERONEGATIVITY; HUMANS; INTERFERON ALFA-2B; ITALY; MALE; MIDDLE AGED; TREATMENT OUTCOME; VON WILLEBRAND DISEASE;

EID: 8244260075     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Rumi MG, Colombo M, Gringeri A, Mannuci PM: High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels. Ann Intern Med 112:379, 1990
2. Triemstra M, Rosendaal FR, Smit C, Van der Ploeg HM, Briet E: Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 123:823, 1995
3. 2b. Hepatology 18:1300, 1993
4. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Payen JL, Sajus M, Costa JM, Vidaud M, Chaput JC, and the Multicenter Study Group: A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 332:1457, 1995
5. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, Frezza M, Noventa F, Pontisso P, Benvegnu L, Casarin C, Alberti A, and th TriVeneto Viral Hepatitis Group: Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 22;700, 1995
6. Peerlinck K, Willems M, Sheng L, Nevens F, Fevery J, Yap SH, Vermylen J: Rapid clearance of hepatitis C virus RNA in peripheral blood mononuclear cells of patients with clotting disorders and chronic hepatitis C treated with alpha-2b interferon is not a predictor for sustained response to treatment. Br J Haematol 86:816, 1994
7. Telfer P, Devereux H, Colvin B, Hayden S, Dusheiko G, Lee C: Alpha interferon for hepatitis C virus infection in haemophilic patients. Haemophilia 1:54, 1995
8. Hanley JP, Jarvis LM, Andrews J, Dennis R, Hayes PC, Piris J, Lee R, Simmonds P, Ludlam CA: Interferon treatment for chronic hepatitis C infection in hemophiliacs. Influence of virus load, genotype, and liver pathology on response. Blood 87:1704, 1996
9. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ, for the Multicenter Hemophilia Cohort Study: Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. J AIDS 6:602, 1993
10. Wright TL, Hollander H, Pu X, Held MJ, Lipson P, Quan S, Polito A, Thaler MM, Bacchetti P, Scharschmidt BF: Hepatitis C in HIV-infected patients with and without AIDS: Prevalence and relationship to patient survival. Hepatology 20:1152, 1994
11. Marcellin P, Martinot-Peignoux M, Elias A, Branger M, Courtois F, Level R, Erlinger S, Benhamou JP: Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay. J Infect Dis 170:433, 1994
12. Rosendaal FR, Smit C, Varekamp I, Brocker-Vriends A, Suurmeijer TPBM, Briet E: AIDS and haemophilia: A study among Dutch haemophiliacs on the psychological impact of the AIDS threat, the prevalence of HIV antibodies and the adoption of measures to prevent HIV transmission. Haemostasis 18:73, 1988
13. Gringeri A, Mannucci PM: National survey of HIV infection in Italian hemophiliacs. Ric Clin Lab 18:75, 1988
14. Evensen SA, Ulstrup J, Skaug K, Froland SS, Glomstein A, Rollag H: HIV infection in Norwegian haemophiliacs: The prevalence of antibodies against HIV in haemophiliacs treated with lyophilized cryoprecipitate from volunteer donors. Eur J Hematol 39:44, 1987
15. Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, Wejstal R, Yun ZB, Weiland O: High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α 2b for 60 weeks. Hepatology 19:280 1994
16. Rumi MG, Colombo M, Romeo R, Colucci G, Gringeri A, Mannucci PM: Serum hepatitis B virus DNA detects cryptic hepatitis B virus infections in multitransfused hemophiliac patients. Blood 75:1654, 1990
17. Rumi MG, Del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, Zahm F, Colombo M: Long-term titrated. recombinant interferon-α 2a in chronic hepatitis C: A randomized controlled trial. J Viral Hep 2:73, 1995
18. Detmer J, Lagier R, Flynn J, Zayari C, Kolberg J, Collins M, Urdea M, Sanchez-Pescador R: Accurate quantification of HCV-RNA from all, HCV genotypes using branched-DNA (bDNA) technology. J Clin Microbiol 34:901, 1996
19. Tagger A, Ribero ML, Tremolada F, Casarin C, Rapicetta M, Cristiano K, Fasola M, Pregliasco F, Profeta ML: Hepatitis C viremia and serologic profile in post-transfusion non-A, non-B hepatitis, in Nishioka K, Suzuki H, Mishiro S, Oda T (els): Viral Hepatitis and Liver Disease. Tokyo, Japan, Springer-Verlag, 1994, p 565
20. Linnen J, Wages J, Zhang-Keck ZY, Fry KE, Krawczynski KZ, Alter H, Koonin E, Gallagher M, Alter M, Hadziyannis S, Karayiannis P, Fung K, Nakatsuji Y, Shih JW, Young L, Piatak M, Hoover C, Fernandez J, Chen S, Zou JC, Morris T, Hyams KC, Ismay S, Lifson JD, Hess G, Foung SKH, Thomas H, Bradley D, Margolis H, Kim JP: Molecular cloning and disease association of hepatitis G virus: A transfusion-transmissible agent. Science 271:505, 1996
21. Tagariello G, Pontisso P, Davoli PG, Ruvoletto MG, Traldi A, Alberti A: Hepatitis C virus genotypes and severity of chronic liver disease in haemophiliacs. Br J Haematol 91:708, 1995
22. Makris M, Preston FE, Rosendaal FR, Underwood JCE, Rice KM, Triger DR: The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 94:746, 1996
23. Mannucci PM: Effects of factor VIII concentrates on the immune system of patients with hemophilia. Thromb Haemostas 74:437, 1995
24. Jarvis LM, Watson HG, McOmish F, Peutherer JF, Ludlam CA, Simmonds P: Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J Infect Dis 170:1018, 1994
25. Devereux H, Telfer P, Brown D, Morris A, Dusheiko G, Emery V, Lee C: Longitudinal genotype analysis and quantification of hepatitis C virus in haemophilic patients receiving interferon-α therapy. J Viral Hep 3:43, 1996
26. Yamada G, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T, Shin S, Tanno M, Urdea MS, Kolberg JA: Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 22:1351, 1995
27. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C, the Collaborative Study Group: Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 122:161, 1995
28. Rumi MG, Del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, Wilber J, Russo A, Colombo M: A prospective randomized trial comparing lymphoblastoid to recombinant alpha 2a interferon as therapy of chronic hepatitis C. Hepatology 24:1366, 1996
29. Pagliaro L, Craxì A, Cammaà C, Tiné F, Di Marco V, Lo Iacono O, Almasio P: Interferon-α for chronic hepatitis C: An analysis of pretreatment clinical predictors of response. Hepatology 19:820, 1994
30. Fletcher ML, Trowell JM, Craske J, Pavier K, Rizza CR: Non-A, non-B hepatitis after transfusion of factor VIII in infrequently treated patients. Br Med J 287:1754, 1983
31. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobayashi M, Hiromitsu K: Factors predictive of response to interferon-a therapy in hepatitis C virus infection. Hepatology 19:1088, 1994
32. 2a therapy in patients with chronic hepatitis C. Dig Dis Sci 39:1273, 1994
33. Telfer PT, Devereux H, Savage K, Scott F, Dhillon AP, Dusheiko G, Lee CA: Chronic hepatitis C virus infection in haemophilic patients: Clinical significance of virai genotype. Thromb Haemostas 74:1259, 1995
34. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH, the Collaborative Study Group: Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med 125:634, 1996
35. Fattovich G, Oiustina G, Favarato S, Ruol A, Investigators of the Italian Association for the Study of the Liver: A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 24:38, 1996